



## Press release

### **STADA Arzneimittel AG and Nidda Healthcare GmbH settle lawsuit and valuation proceedings with shareholders; timely registration of squeeze out expected**

**Bad Vilbel, 4.11.2020** – On 15 October 2020, STADA Arzneimittel AG (STADA) entered into a settlement agreement with the plaintiffs regarding the challenges to all resolutions of its annual general meeting of 14 May 2020. All resolutions are therefore valid and binding. Furthermore, on 30 October 2020, Nidda Healthcare GmbH (Nidda) and all remaining applicants entered into a settlement agreement to terminate appraisal proceedings relating to the compensation and guaranteed dividend payable under the domination and profit and loss transfer agreement between STADA and Nidda, which were pending before the Higher Regional Court of Frankfurt am Main. As part of this comprehensive settlement, Nidda has undertaken to make a one-time payment of EUR 0.10 per outstanding STADA share to all remaining shareholders of STADA. The payment shall be made together with the cash consideration of the squeeze out. This payment obligation is subject to the condition precedent that the squeeze out resolution adopted by the extraordinary general meeting of STADA on 24 September 2020 (Squeeze Out Resolution) will be registered with the commercial register prior to the end of 2020. STADA expects a timely registration of the Squeeze Out Resolution with the commercial register. Upon registration, Nidda and STADA will provide further details as to the pay out of the squeeze out compensation. With the registration of the squeeze out, Nidda will hold 100 % of the STADA shares without any remaining minority shareholders.



**About STADA Arzneimittel AG**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

***Additional information for journalists:***

STADA Arzneimittel AG

Media Relations

Stadastrasse 2-18

61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

Fax: +49 (0) 6101 603-215

E-Mail: [press@stada.de](mailto:press@stada.de)

Or visit us on the Internet at [www.stada.com/press](http://www.stada.com/press)

***Additional information for capital market participants:***

STADA Arzneimittel AG

Investor & Creditor Relations

Stadastrasse 2-18

61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: [ir@stada.de](mailto:ir@stada.de)

Or visit us on the Internet at [www.stada.com/investor-relations](http://www.stada.com/investor-relations)

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au